Elite in Diabetic Ketoacidosis

David Z. Cherney

585 University Ave, 8N-845, M5G 2N2, 
Toronto, ON, CA 
Elite in Diabetic Ketoacidosis
585 University Ave, 8N-845, M5G 2N2, 
Toronto, ON, CA 
OverviewLocationsClinical Research

Overview

David Cherney practices in Toronto, Canada. Mr. Cherney and is rated as an Elite expert by MediFind in the treatment of Diabetic Ketoacidosis. His top areas of expertise are Type 2 Diabetes (T2D), Type 1 Diabetes (T1D), Diabetic Nephropathy, Diabetic Ketoacidosis, and Kidney Transplant.

His clinical research consists of co-authoring 389 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 13 articles in the study of Diabetic Ketoacidosis.

Gender
Male

Locations

585 University Ave, 8N-845, M5G 2N2, Toronto, ON, Canada

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

DAPASALT: An Open Label, Phase IV, Mechanistic, Study to Evaluate the Natriuretic Effect of 2-Week Dapagliflozin Treatment in Type 2 Diabetes Mellitus Patients With Impaired Renal Function
DAPASALT: An Open Label, Phase IV, Mechanistic, Study to Evaluate the Natriuretic Effect of 2-Week Dapagliflozin Treatment in Type 2 Diabetes Mellitus Patients With Impaired Renal Function
Enrollment Status: Completed
Publish Date: April 24, 2025
Intervention Type: Drug
Study Drug: Dapagliflozin
Study Phase: Phase 4
Effects of DPP-4 Inhibitor Therapy on Renal Sodium Handling and Renal Hemodynamics in Type 2 Diabetes Patients. The INDORSE Study: Inhibition of Dipeptidyl Peptidase IV: Outcomes on Renal Sodium Excretion
Effects of DPP-4 Inhibitor Therapy on Renal Sodium Handling and Renal Hemodynamics in Type 2 Diabetes Patients. The INDORSE Study: Inhibition of Dipeptidyl Peptidase IV: Outcomes on Renal Sodium Excretion
Enrollment Status: Completed
Publish Date: April 05, 2018
Intervention Type: Drug, Other
Study Phase: Phase 4
View 1 Less Clinical Trial

389 Total Publications

SGLT2 Inhibitors and Risk for Hyperkalemia Among Individuals Receiving RAAS Inhibitors.
SGLT2 Inhibitors and Risk for Hyperkalemia Among Individuals Receiving RAAS Inhibitors.
Journal: JAMA internal medicine
Published: April 28, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Cherney's expertise for a condition
ConditionClose
View All 32 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile